Screening for Substance Use Disorders/Opioid Use Disorder

This inaugural National Strategy proposes bold, targeted, and consequential actions to bend the curve on overdose deaths in the immediate term and reduce substance use and its damaging consequences in the US over the longer term.

These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which assist women who are pregnant, or have recently had a child, and who use alcohol or drugs or who have a substance use disorder.

SAMHSA offers evidence-based resources to help providers screen, diagnose, and deliver integrated care to patients with co-occurring disorders.

In this webinar, Drs. John Iskander and Suzanne Gilboa discuss what CDC and its partners are doing to reduce prenatal substance exposure and how screening and brief interventions may reduce prenatal substance exposure and improve the health of women and infants.

The following checklist intends to support health care teams in providing evidence-based recommendations for treating pregnant and postpartum patients with OUD. The checklist is divided into five sections, sequenced by timing of presentation to care.

This screening device is often used as a way to begin discussion about drug and alcohol use. Any woman who answers yes to one or more questions should be referred for further assessment.

This revised version of the CRAFFT screening tool incorporates changes that enhance the sensitivity of this well-validated and widely-utilized adolescent substance use screening tool to accurately identify adolescents at risk for a substance use disorder. It also presents new recommended clinician talking points, informed by the latest science and clinician feedback.

The Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool consists of a combined screening component (TAPS-1) followed by a brief assessment (TAPS-2) for those who screen positive.